- Technology

Biologics development is lengthy and costly. It takes more than 2 years to bring a candidate therapy to human trials. This prevents timely intervention during infectious disease outbreaks resulting in millions of fatalities every year.

Conventional Biomanufacturing

TYCHAN’s Integrated Rapid Response Platform

Tychan’s technology platform integrates innovations in data analytics, bio-manufacturing processes and regulatory sciences to bring candidate biologics to human trials faster. We use convergent analytics to define molecular fingerprints for reliable tracking of safety and potency of biologics throughout the manufacturing process – from cell selection to final product. Using this approach, we have brought a first-in-class anti-Zika virus therapeutic into Phase 1 trials within 12 months of conceptualization.

- Pipeline


Tyzivumab is a first-in-class monoclonal antibody designed and engineered to neutralize Zika virus by binding to a specific quaternary epitope of the envelope (E) protein on virus surface.

About Zika Virus

Zika virus (ZIKV) has emerged to become a major health concern in many parts of the tropical world. This flavivirus is transmitted by the same Aedes mosquitoes that spread the dengue virus (DENV), and hence ZIKV has the potential to be as widely distributed as DENV globally. Whilst mostly a mild, self-limiting viral infection, epidemiological observations now reveal a strong link between infection of pregnant women and severe neurological complications, including microcephaly, in the developing fetus. Rarely, infection in otherwise healthy adults can also lead to the development of neurological complications in the form of Guillain-Barré syndrome. With no approved vaccine, there is an urgent need for a safe therapy to reduce viral spread and lower the risk of congenital infection and Guillain-Barré syndrome.

- News